Altimmune to Participate at Two Upcoming ConferencesGlobeNewswireMay 01, 2024GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences:
BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern TimeGLP-1-Based Therapeutics Summit (Philadelphia, PA)Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver DiseaseWednesday, May 15, 2024Presentation at 10:00 am Eastern TimeTitle: Attaining Product Differentiation through Improved Patient Segmentation & EfficiencyThursday, May 16, 2024Presentation at 1:30pm Eastern TimeAbout Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Altimmune Investor Contact:Richard EisenstadtChief Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
COMTEX_451712319/2010/2024-05-01T07:30:33
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences:
BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern TimeGLP-1-Based Therapeutics Summit (Philadelphia, PA)Title: Focusing on the Use of GLP-1s in Treating MASH & Fatty Liver DiseaseWednesday, May 15, 2024Presentation at 10:00 am Eastern TimeTitle: Attaining Product Differentiation through Improved Patient Segmentation & EfficiencyThursday, May 16, 2024Presentation at 1:30pm Eastern TimeAbout Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Altimmune Investor Contact:Richard EisenstadtChief Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone: 646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
COMTEX_451712319/2010/2024-05-01T07:30:33
10.00% $0.89
